<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pediatr Rheumatol Online J</journal-id><journal-id journal-id-type="iso-abbrev">Pediatr Rheumatol Online J</journal-id><journal-title-group><journal-title>Pediatric Rheumatology Online Journal</journal-title></journal-title-group><issn pub-type="epub">1546-0096</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4044605</article-id><article-id pub-id-type="publisher-id">1546-0096-11-S2-P289</article-id><article-id pub-id-type="doi">10.1186/1546-0096-11-S2-P289</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>PReS-FINAL-2299: Novel biomarkers for the assessment of pediatric systemic lupus erythematosus nephritis (preliminary report)</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Koutsonikoli</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" corresp="yes" id="A2"><name><surname>Trachana</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Tzimouli</surname><given-names>V</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Farmaki</surname><given-names>E</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Printza</surname><given-names>N</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Garyfallos</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Galanopoulou</surname><given-names>V</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Pratsidou-Gertsi</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Papachristou</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Kanakoudi-Tsakalidou</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>1st Department of Pediatrics, Aristotle University of Thessaloniki, "Hippocration" General Hospital, Thessaloniki, Greece</aff><aff id="I2"><label>2</label>4th Department of Internal Medicine, Aristotle University of Thessaloniki, "Hippocration" General Hospital, Thessaloniki, Greece</aff><aff id="I3"><label>3</label>Department of Rheumatology, "Papageorgiou" General Hospital, Thessaloniki, Greece</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>5</day><month>12</month><year>2013</year></pub-date><volume>11</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">Proceedings of 20th Pediatric Rheumatology European Society (PReS) Congress</named-content><named-content content-type="supplement-sponsor">The publication charges for this supplement were funded by the PReS 2013 congress.</named-content></supplement><fpage>P289</fpage><lpage>P289</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Koutsonikoli et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Koutsonikoli et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.ped-rheum.com/content/11/S2/P289"/><conference><conf-date>25-29 September 2013</conf-date><conf-name>20th Pediatric Rheumatology European Society (PReS) Congress</conf-name><conf-loc>Ljubljana, Slovenia</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Nephritis is the most common severe manifestation of pediatric Systemic Lupus Erythematosus (pSLE) and the major predictor of poor prognosis. Research for the detection of novel and accurate biomarkers, predictive of the nephritis outcome, is globally in progress. Ethnicity affects the disease outcome but data on purely Caucasian populations are still limited.</p></sec><sec><title>Objectives</title><p>The exploration of the role of serum biomarkers, namely anti-nucleosome antibodies (anti-NCS), anti-C1q antibodies (anti-C1q), anti-glomerular basement membrane antibodies (anti-GBM) and high mobility group box 1 protein (HMGB1) in pSLE nephritis and the association of their levels with pSLE nephritis and pSLE disease activity.</p></sec><sec sec-type="methods"><title>Methods</title><p>Twenty-four patients (16 female) with pSLE nephritis (44 serum samples, 22 in active nephritis) and 21 patients (18 female) with pSLE without nephritis (32 serum samples, 19 in active pSLE) were enrolled in the study. The disease control group included 17 patients with nephritis of other causality (Henoch-Sch&#x000f6;nlein purpura nephritis, IgA nephropathy, postinfectious glomerulonephritis, membranous glomerulonephritis), who provided equal serum samples. The SLICC renal activity score was applied for assessing pSLE nephritis disease activity and ECLAM for global pSLE disease activity. The biomarkers' levels were determined by ELISA.</p></sec><sec sec-type="results"><title>Results</title><p>The pSLE nephritis patients had significantly higher serum levels of anti-NCS [median: 48.89 (IQR: 31.48-80.81) U/ml versus 12.5 (11.5-27.8) U/ml, p &#x0003c; 0.001], anti-C1q [22.75 (12.77-56.4) U/ml versus 12.5 (12.5-12.5) U/ml, p &#x0003c; 0.001], anti-GBM [3.88 (2.25-6.94) U/ml versus 2.2 (2.2-2.4) U/ml, p = 0.002] and HMGB1 [9.9 (5.7-32.23) ng/ml versus 2.5 (2.5-2.5) ng/ml, p &#x0003c; 0,001], than the patients with nephritis of other causality. Serum anti-GBM levels were significantly higher in the pSLE nephritis patients compared to the pSLE patients without nephritis [3.88 (2.25-6.94) U/ml versus 2.25 (2.2-2.83) U/ml, p = 0.014], while this was not true for the rest of the biomarkers. In the pSLE nephritis patients no correlation was found between serum anti-GBM levels and pSLE nephritis disease activity. Serum anti-NCS and anti-C1q levels were positively correlated with the ECLAM score in the pSLE patients as a whole (p = 0.002, rho = 0.492 and p = 0.007, rho = 0.461, respectively).</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In this pure Caucasian Northern Greek pSLE population, high serum anti-GBM levels were found to be associated with the presence of nephritis, but not with the nephritis disease activity. Serum anti-GBM, anti-NCS, anti-C1q and HMGB1 may be used to differentiate patients with pSLE nephritis from patients with nephritis of other causality. Furthermore, serum anti-NCS and anti-C1q may be useful for the estimation of pSLE disease activity.</p></sec><sec><title>Disclosure of interest</title><p>None declared.</p></sec></body></article>